AETHLON MEDICAL, INC. 8-K
false
0000882291
0000882291
2024-07-01
2024-07-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 1, 2024
Aethlon
Medical, Inc.
(Exact name of registrant as specified in its
charter)
| Nevada |
001-37487 |
13-3632859 |
|
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
11555
Sorrento Valley Road, Suite
203
San Diego, California |
92121 |
| (Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (619) 941-0360
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
Common Stock, $0.001 par value per share |
AEMD |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
| Item 4.01 |
Changes in Registrant’s Certifying Accountant |
Dismissal of Independent Registered Public
Accounting Firm
On July 1, 2024, Aethlon
Medical, Inc. (the “Company”) dismissed Baker Tilly US, LLP (“Baker Tilly”) as the Company’s
independent registered public accounting firm effective as of that date. The board of directors of the Company (the “Board”)
approved the dismissal of Baker Tilly on July 1, 2024, based upon the recommendation of the audit committee of the Board (the “Audit
Committee”).
The report of Baker Tilly as of and for the fiscal
years ended March 31, 2023 and 2024 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as
to uncertainty, audit scope, or accounting principles, except that Baker Tilly’s report as of and for the fiscal year ended March
31, 2024 contained an explanatory paragraph expressing substantial doubt about the ability of the Company to continue as a going concern.
During the fiscal years ended March 31, 2023 and
2024, and the subsequent interim period through July 1, 2024, there were (i) no “disagreements,” as that term is defined in
Item 304(a)(1)(iv) of Regulation S-K, with Baker Tilly on any matter of accounting principles or practices, financial statement disclosure,
or auditing scope or procedures, any of which, if not resolved to Baker Tilly’s satisfaction, would have caused it to make reference
to the subject matter of any such disagreement in connection with its reports for such fiscal years and (ii) no “reportable events,”
as that term is defined in Item 304(a)(1)(v) of Regulation S-K, during the fiscal years ended March 31, 2023 and 2024 requiring disclosure
pursuant to paragraph (a)(1)(v) of Item 304 of Regulation S-K and the related instructions to Item 304 of Regulation S-K.
In accordance with Item 304(a)(3) of Regulation
S-K, the Company provided Baker Tilly with a copy of this Current Report prior to its filing with the Securities and Exchange Commission
(“SEC”) and requested that Baker Tilly furnish it with a letter addressed to the SEC stating whether or not it agrees with
the above statements. A copy of Baker Tilly’s letter, dated July 3, 2024, is filed as Exhibit 16.1 to this Current Report on Form
8-K.
Engagement
of New Independent Registered Public Accounting Firm
On July 1, 2024, the Company engaged Haskell &
White LLP (“H&W”) to serve as the Company’s independent registered public accounting firm, effective immediately.
The Audit Committee approved the decision to engage H&W and appointed H&W as the Company’s independent registered public
accounting firm for the fiscal year ending March 31, 2025.
During the fiscal years ended March 31, 2023 and
2024, and the subsequent interim period through July 1, 2024, neither the Company nor anyone acting on its behalf, consulted H&W regarding
either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion
that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company
that H&W concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial
reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or
(iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 3, 2024 |
Aethlon Medical, Inc. |
| |
|
|
| |
|
|
| |
By: |
/s/ James B. Frakes |
| |
Name:
|
James B. Frakes
Interim Chief Executive Officer and Chief Financial Officer |
